Sauvie is a biotechnology company developing CAM-V™ antibodies and bispecific immune cell engagers to enhance the efficacy of natural killer cells in targeting and eliminating cancer cells. By focusing on immuno-oncology, Sauvie aims to provide patients with access to effective cancer therapies that address the limitations of current treatment options.
Funding
$780K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer therapies often have limitations in efficacy and can cause significant side effects, highlighting the need for more targeted and effective treatment options. Natural killer (NK) cells are a type of immune cell that can target and kill cancer cells, but their activity can be suppressed in the tumor microenvironment. Enhancing the ability of NK cells to recognize and eliminate cancer cells remains a challenge in immuno-oncology.
Solution
Sauvie is developing CAM-V™ antibodies and bispecific immune cell engagers designed to enhance the efficacy of natural killer (NK) cells in targeting and eliminating cancer cells. Their bispecific engagers are designed to activate NK cells to kill cancer cells without mediating fratricide. The company's approach focuses on immuno-oncology to provide patients with access to effective cancer therapies that address the limitations of current treatment options. Sauvie's technology aims to overcome the suppressive effects of the tumor microenvironment, improving NK cell-mediated cancer cell killing.
Target Audience
Sauvie's primary target audience includes patients with cancer and the healthcare providers who treat them, as well as pharmaceutical companies seeking to develop novel immuno-oncology therapies.
Features
- CAM-V™ antibodies designed to enhance NK cell activity against cancer cells.
- Bispecific immune cell engagers that activate NK cells to kill cancer cells.
- Bispecific engagers eliminate cancer metastasis in NK humanized NOG mice.
- High affinity and specificity anti-HER2 single-domain antibody (VHH) that targets trastuzumab’s epitope.
- Nanobody-based NK cell engager technology.